Novel monoclonal antibodies against pancreatic juice from pancreatic cancer patients and their possible application in differential diagnosis

International Journal of Molecular Medicine

Volumn 28, Issue 4, 2011, Pages 599-603

  Hamabashiri, Masato ^a   Daichou, Aya ^a   Yasumoto, Makiko ^b   Ogasawara, Sachiko ^b   Nishinakagawa, Takuya ^a   Enjoji, Munechika ^a   Ohshima, Kouichi ^b   Yano, Hirohisa ^b   Nakashima, Manabu ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Monoclonal antibody; Pancreatic cancer; Subtractive immunization

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2P 1 17 1; MONOCLONAL ANTIBODY 2P 1 2 1; MONOCLONAL ANTIBODY 6P 3 2 4; MONOCLONAL ANTIBODY 7P 9 11 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CHRONIC PANCREATITIS; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HYBRIDOMA; IMMUNIZATION; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS JUICE; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; DIAGNOSIS, DIFFERENTIAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; HYBRIDOMAS; MICE; MICE, INBRED BALB C; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC;

EID: 79960781726     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.717     Document Type: Article

References (17)

1. Matsuno S, Egawa S, Fukuyama S, et al: Pancreatic cancer registry of the Japan Pancreas Society. Summary of 20 years. Pancreas 28: 219-230, 2004. (Pubitemid 38437313)
2. Seino T, Nakadaira H, Endoh K and Yamamoto M: Changes in pancreatic cancer mortality, period patterns, and birth cohort patterns in Japan: analysis of mortality data in the period 1968-2002. Environ Health Prev Med 13: 234-242, 2008.
3. Egawa S, Takeda K, Akada M, Abe H, Yokoyana T, Motoi F, Fukuyama S, Sunamura M and Matsuno S: Small pancreatic cancer: from the national pancreatic cancer registry. J Jpn Pancreas Soc 19: 558-565, 2004 (In Japanese).
4. Koopmann J, Fedarko NS, Jain A, et al: Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13: 487-491, 2004. (Pubitemid 38737477)
5. Chen R, Pan S, Brentnall TA and Aebersold R: Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomic 4: 523-533, 2005. (Pubitemid 40590569)
6. Steinbrg W: The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol 85: 350-355, 1990.
7. Takayama R, Nakagawa H, Saai A, et al: Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol 45: 52-59, 2010.
8. Grote T and Logsdon CD: Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol 23: 508-514, 2007. (Pubitemid 47356736)
9. Tonack S, Aspinall-O'Dea M, Neoptolemos JP and Costello E: Pancreatic cancer: proteomic approaches to a challenging disease. Pancreatology 9: 567-576, 2009.
10. Sleister HM and Rao AG: Subtractive immunization: a tool for the generation of discriminatory antibodies to proteins of similar sequence. J Immunol Methods 26: 213-220, 2002. (Pubitemid 34175230)
11. Zijlstra A, Testa JE and Quigley JP: Targeting the proteome/epitome, implementation of subtractive immunization. Biochem Biophys Res Commun 202: 733-744, 2003. (Pubitemid 36384917)
12. Sleister HM and Rao AG: Strategies to generate antibodies capable of distinguishing between proteins with >90% amino acid identity. J Immunol Methods 252: 121-129, 2001. (Pubitemid 32382095)
13. Matthew WD and Sandrock AW Jr: Cyclophosphamide treatment used to manipulate the immune response for the production of monoclonal antibodies. J Immunol Methods 100: 73-82, 1987. (Pubitemid 17088906)
14. Dennis J, Waller C, Timpl R and Schirrmacher V: Surface sialic acid reduces attachment of metastatic tumor cells to collagen type IV and fibronectin. Nature 300: 274-276, 1982. (Pubitemid 13234738)
15. Uemura T, Shiozaki K, Yamaguchi K, et al: Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. Oncogene 28: 1218-1229, 2009.
16. Dube DH and Bertozzi CR: Glycans in cancer and inflammation - potential for therapeutics and diagnostics. Nat Rev Drug Discov 4: 477-488, 2005. (Pubitemid 40861990)
17. Hakomori S: Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 99: 10231-10233, 2002.